Similar articles

• Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.

  Hawk AF, Chang EY, Shields SM, Simpson KN. Hawk AF, et al. Obstet Gynecol. 2013 Sep;122(3):579-85. doi: 10.1097/AOG.0b013e31829f8814. Obstet Gynecol. 2013. PMID: 23921866
• In reply.

  Hawk AF, Chang EY, Shields SM, Simpson KN. Hawk AF, et al. Obstet Gynecol. 2013 Dec;122(6):1306-7. doi: 10.1097/AOG.0000000000000037. Obstet Gynecol. 2013. PMID: 24264706 No abstract available.
• Costs and benefits of non-invasive fetal RhD determination.

  Teitelbaum L, Metcalfe A, Clarke G, Parboosingh JS, Wilson RD, Johnson JM. Teitelbaum L, et al. Ultrasound Obstet Gynecol. 2015 Jan;45(1):84-8. doi: 10.1002/uog.14723. Ultrasound Obstet Gynecol. 2015. PMID: 25380024
• Economics of antenatal prophylaxis.

  Cairns JA. Cairns JA. Br J Obstet Gynaecol. 1998 Nov;105 Suppl 18:19-22. doi: 10.1111/j.1471-0528.1998.tb10287.x. Br J Obstet Gynaecol. 1998. PMID: 9863974 Review. No abstract available.
• [Economic analysis of the prevention of anti-D immunization].

  Ravinet J, Carbonne B. Ravinet J, et al. J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S104-1S111. J Gynecol Obstet Biol Reprod (Paris). 2006. PMID: 16495835 Review. French.